Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E58.05 EPS (ttm)1.12 Insider Own0.10% Shs Outstand1.59B Perf Week2.33%
Market Cap103.54B Forward P/E11.43 EPS next Y5.69 Insider Trans-3.22% Shs Float1.57B Perf Month14.47%
Income1.82B PEG3.90 EPS next Q1.05 Inst Own73.20% Short Float1.31% Perf Quarter4.34%
Sales20.44B P/S5.07 EPS this Y-57.20% Inst Trans0.38% Short Ratio1.61 Perf Half Y10.97%
Book/sh1.08 P/B60.20 EPS next Y17.35% ROA6.40% Target Price71.45 Perf Year36.44%
Cash/sh5.26 P/C12.36 EPS next 5Y14.90% ROE44.60% 52W Range47.47 - 69.66 Perf YTD0.93%
Dividend2.04 P/FCF- EPS past 5Y-17.80% ROI16.80% 52W High-6.65% Beta-
Dividend %3.14% Quick Ratio1.30 Sales past 5Y7.00% Gross Margin79.40% 52W Low36.97% ATR1.45
Employees26000 Current Ratio1.40 Sales Q/Q10.50% Oper. Margin21.60% RSI (14)67.18 Volatility2.75% 2.15%
OptionableYes Debt/Eq8.62 EPS Q/Q4.90% Profit Margin8.90% Rel Volume1.41 Prev Close66.07
ShortableYes LT Debt/Eq6.06 EarningsApr 23 BMO Payout153.50% Avg Volume12.84M Price65.02
Recom2.30 SMA207.23% SMA509.56% SMA20010.22% Volume18,067,584 Change-1.59%
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-15-13Reiterated R. F. Lafferty Buy $47.90 → $61
Apr-29-13Reiterated Barclays Equal Weight $41 → $44
Apr-15-13Reiterated Barclays Equal Weight $37 → $41
Apr-27-15 03:12PM  Will Express Scripts (ESRX) Disappoint Earnings in Q1? - Analyst Blog
12:17PM  Gilead Sciences: Still the One to Beat in Hepatitis-C at Barrons.com
09:08AM  5 Rocket Stocks That Are Ready for Blastoff at TheStreet
Apr-26-15 08:02AM  4 Top-Rated Drugmakers Reporting Earnings This Week at Investor's Business Daily
Apr-25-15 05:00PM  Bristol-Myers says hepatitis C drug combination succeeds in study Reuters
10:22AM  Enanta Pharmaceuticals Announces Preliminary Data from AbbVies Phase 3b RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment Presented at The International Liver Congress 2015 at noodls
10:20AM  AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress 2015 at noodls
10:00AM  AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress 2015 PR Newswire
07:00AM  Inversion Deals Aren't Dead, They're Just More Low-Key
07:00AM  Inversion Deals Arent Dead, Theyre Just More Low-Key: Real M&A at Bloomberg
Apr-24-15 05:36PM  AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog
03:16PM  Eli Lilly (LLY) Earnings Analysis: By the Numbers
09:48AM  AbbVie Hepatitis C Drug Granted Priority FDA Review at The Wall Street Journal
03:32AM  AbbVie (ABBV) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
01:12AM  U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C at noodls
01:00AM  Merck oral hepatitis C regimen shows 95 pct cure rate
12:45AM  U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C PR Newswire
Apr-23-15 07:45PM  Biogen Earnings Preview: What To Look For at Investor's Business Daily
02:14PM  AbbVie Profit Rises on Broad Sales Growth at The Wall Street Journal
01:45PM  The overseas tax tactic is back
12:17PM  Doomsday Plan for AbbVie Means Preserving Profits at All Costs at Bloomberg
11:46AM  AbbVie Beats Q1 Estimates; Novartis, Alexion Mixed at Investor's Business Daily
11:18AM  AbbVie Beats Earnings on Humira and HCV Sales, Ups View - Analyst Blog
11:07AM  Shire Gets Dropped from AQR Capitals Portfolio
10:49AM  AbbVie: Wait, I Thought It Was Good News? at Barrons.com
10:48AM  AbbVie raises outlook as Humira again delivers earnings beat
10:45AM  Abbvie's CEO Gonzalez: We're Now In Pharma's 'Top Tier' at Forbes
09:29AM  GM, P&G drop; Caterpillar, Dunkin Brands jumps at MarketWatch
09:18AM  AbbVie (ABBV) Tops 1Q Earnings and Revenue Estimates - Tale of the Tape
09:16AM  Morning Movers: AbbVie Gains on Earnings, Hepatitis-C Sales; General Motors Drops at Barrons.com
09:00AM  AbbVie Inc Earnings Call scheduled for 9:00 am ET today
08:52AM  Enanta Announces U.S. FDA Grants Priority Review for AbbVies Investigational, All-Oral, Interferon-Free Treatment Regimen for Genotype 4 Chronic Hepatitis C Infection at noodls
08:21AM  AbbVie tops Street 1Q forecasts
08:17AM  AbbVie Reports First-Quarter 2015 Financial Results at noodls
08:00AM  ABBVIE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:56AM  AbbVie Profit Tops Estimates as Hepatitis C Drug Sales Increase at Bloomberg
07:55AM  Drugmaker AbbVie profit rises on sales of Humira
07:48AM  AbbVie Reports First-Quarter 2015 Financial Results PR Newswire
07:07AM  Q1 2015 AbbVie Inc Earnings Release - Before Market Open
Apr-22-15 08:01PM  Gilead Earnings Preview: What You Should Know at Investopedia
07:31PM  Forget Google: 5 Top Stocks With Earnings Thursday at Investor's Business Daily
01:21PM  Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog
08:30AM  5 Cheap Large Cap Stocks to Buy in an Expensive Stock Market at 24/7 Wall St.
Apr-21-15 06:15PM  AbbVie Earnings: What to Watch at The Wall Street Journal
05:10PM  Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog
03:14PM  Is AbbVie (ABBV) Set to Top 1Q Earnings on Humira & HCV? - Analyst Blog
01:47PM  Bulls chase AbbVie into earnings
09:09AM  Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog
Apr-20-15 04:08PM  Informatica MAE Clause: Highlights for Investors
01:29PM  Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog
09:10AM  3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings at 24/7 Wall St.
Apr-17-15 06:07PM  MAE Clause: What Could Stop the Informatica Merger?
05:07PM  AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. at noodls
04:47PM  AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. PR Newswire
Apr-16-15 06:14PM  AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog
02:05PM  Can the Informatica Transaction Get Competitive?
01:45PM  The Informatica Merger Spread Currently Yields About 4%
10:50AM  Receptos MS Drug Succeeds Against Ulcerative Colitis at Investor's Business Daily
09:20AM  Maverick Capital Eliminates Its Position in AbbVie
09:19AM  Highlights of Maverick Capitals Top Sold-Out Positions
08:30AM  Healthcare ETFs in Focus Post JNJ Earnings Beat - ETF News And Commentary
Apr-15-15 07:48PM  Enanta Pharmaceuticals Announces AbbVies Investigational Treatment Regimen for Genotype 1 Chronic Hepatitis C Granted Priority Review in Japan at noodls
07:45PM  AbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan at noodls
07:00PM  AbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan PR Newswire
06:06PM  Abbott Labs, Sekisui Medical to Offer Coagulation Tests - Analyst Blog
02:41PM  AbbVie: Strong Data, Once Daily Dose 'Necessary to Ensure Strong Commercial Success' at Barrons.com
11:49AM  Pfizer, Biogen, AbbVie Get Good Drug-Trial News at Investor's Business Daily
10:52AM  3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog
10:40AM  AbbVie to Host First-Quarter Earnings Conference Call at noodls
10:05AM  AbbVie to Host First-Quarter Earnings Conference Call PR Newswire
Apr-14-15 10:38PM  How Gilead Plans to Keep Competitors in Check at Investopedia
05:48PM  J&J Earnings Beat Estimates; Guidance Mixed at Investor's Business Daily
05:05PM  Life Time Fitness Deal: Material Adverse Change Explained, Part 2
05:05PM  Life Time Fitness Deal: Material Adverse Change Explained, Part 3
04:56PM  Medtronic PLC (MDT), AbbVie Inc. (ABBV), Humana Inc (HUM): Rock Springs Capital Rides Healthcare Stocks to Big Q1 Gains at Insider Monkey
04:06PM  Magnetar Capital Lowers Its Stake in Shire
03:19PM  AbbVie (ABBV) Stock Rises Today on Bullish Analyst Notes at TheStreet
02:25PM  AbbVie: The Old & the New at Barrons.com
12:50PM  J&J cuts guidance as strong dollar hits sales at Financial Times
11:12AM  J&J Earnings Beat Estimates; Guidance Mixed at Investor's Business Daily
12:00AM  U.S. prescription drug spending rose 13 pct in 2014-IMS report
Apr-13-15 01:36PM  AbbVie (ABBV) Stock Opens Higher, Then Falls Today Following Analyst Upgrade at TheStreet
12:03PM  Chinese Stocks Lead Stock Market Higher at Investor's Business Daily
11:19AM  AbbVie Upgraded On $7.8 Billion Imbruvica Potential at Investor's Business Daily
10:46AM  One Analyst Changes His Tune on AbbVie and its Pharmacyclics Deal at The Wall Street Journal
08:31AM  Analysts' Actions -- AbbVie, Freeport-McMoRan, Nielsen and More
07:43AM  Early movers: SHLD, UNH, ABBV, NFLX, UPS & more at CNBC
Apr-10-15 10:45AM  5 Stocks Ready for Breakouts at TheStreet
10:10AM  Gilead: Little Hep C Competition, But What About Pricing? at Barrons.com
09:23AM  Venture capitalists ride biotech wave one drug at a time
Apr-09-15 01:10PM  Merck's HCV Combo Drug Gets Two Breakthrough Status - Analyst Blog
10:50AM  Mylan Proposes to Acquire Perrigo, Sets Both Stocks Soaring - Analyst Blog
09:45AM  Cowen Thinks 3 Life Science Stocks Can Beat Earnings Estimates at 24/7 Wall St.
Apr-08-15 05:56PM  FDA Speeds Merck Reviews For Hep C's Sickest
12:17PM  Biosimilar drugs: spot the difference at Financial Times
10:30AM  Bet on M&A Frenzy with These ETFs and Stocks - ETF News And Commentary
04:40AM  AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress 2015 at noodls
04:19AM  AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress 2015 PR Newswire
Apr-07-15 02:50PM  Repros Gets EU Update on Secondary Hypogonadism Drug - Analyst Blog
Apr-06-15 10:35AM  What's Next For The Thousands Of Angry Men Suing Over Testosterone? at Forbes
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 02Sale60.3012,314742,534106,954Mar 03 06:07 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 02Sale60.3025,0001,507,500274,116Mar 03 06:10 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 27Sale60.472,112127,706104,555Mar 03 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 27Sale60.512,074125,492123,860Mar 03 06:07 PM
HURWICH THOMAS A.VP, ControllerFeb 27Sale60.571,18571,77770,322Mar 03 06:06 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 17Sale58.7024114,147106,592Feb 19 05:51 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 09Option Exercise24.072,25054,1643,168Feb 11 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Option Exercise24.078,495204,501188,563Dec 22 05:22 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Sale68.008,495577,660180,068Dec 22 05:22 PM
HURWICH THOMAS A.VP, ControllerNov 24Sale67.811,500101,71763,211Nov 26 05:00 PM
HURWICH THOMAS A.VP, ControllerNov 06Option Exercise24.0710,000240,73171,448Nov 07 05:57 PM